Cargando…

Clinical Outcomes of Genotype-Matched Therapy for Recurrent Gynecological Cancers: A Single Institutional Experience

Recent advances in next-generation sequencing and genome medicine have contributed to treatment decisions in patients with cancer. Most advanced gynecological cancers develop resistance to chemotherapy and have a poor prognosis. Therefore, we conducted genomic tests in gynecological tumors to examin...

Descripción completa

Detalles Bibliográficos
Autores principales: Sawada, Kiyoka, Nakayama, Kentaro, Nakamura, Kohei, Yoshimura, Yuki, Razia, Sultana, Ishikawa, Masako, Yamashita, Hitomi, Ishibashi, Tomoka, Sato, Seiya, Kyo, Satoru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8535840/
https://www.ncbi.nlm.nih.gov/pubmed/34683075
http://dx.doi.org/10.3390/healthcare9101395
_version_ 1784587880959574016
author Sawada, Kiyoka
Nakayama, Kentaro
Nakamura, Kohei
Yoshimura, Yuki
Razia, Sultana
Ishikawa, Masako
Yamashita, Hitomi
Ishibashi, Tomoka
Sato, Seiya
Kyo, Satoru
author_facet Sawada, Kiyoka
Nakayama, Kentaro
Nakamura, Kohei
Yoshimura, Yuki
Razia, Sultana
Ishikawa, Masako
Yamashita, Hitomi
Ishibashi, Tomoka
Sato, Seiya
Kyo, Satoru
author_sort Sawada, Kiyoka
collection PubMed
description Recent advances in next-generation sequencing and genome medicine have contributed to treatment decisions in patients with cancer. Most advanced gynecological cancers develop resistance to chemotherapy and have a poor prognosis. Therefore, we conducted genomic tests in gynecological tumors to examine the efficacy and clinical feasibility of genotype-matched therapy. Target sequencing was performed in 20 cases of gynecological cancers (cervical cancer, 6; endometrial cancer, 6; and ovarian cancer, 6). Both actionable and druggable genes were identified in 95% (19/20) of the cases. Among them, seven patients (35%) received genotype-matched therapy, which was effective in three patients. Of the three patients, one patient with a PTEN mutation received everolimus, another patient with a TSC2 mutation received everolimus and letrozole, and the patient with a BRIP1 mutation received olaparib. Subsequently, disease control in these three patients lasted for more than half a year. However, all patients relapsed between 9 and 13 months after the initiation of genotype-matched therapy. In this study, the response rate of genotype-matched therapy was 43% (3/7), which may have contributed to improved prognoses. Therefore, genotype-matched therapies may help patients with refractory gynecological cancers achieve better outcomes.
format Online
Article
Text
id pubmed-8535840
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-85358402021-10-23 Clinical Outcomes of Genotype-Matched Therapy for Recurrent Gynecological Cancers: A Single Institutional Experience Sawada, Kiyoka Nakayama, Kentaro Nakamura, Kohei Yoshimura, Yuki Razia, Sultana Ishikawa, Masako Yamashita, Hitomi Ishibashi, Tomoka Sato, Seiya Kyo, Satoru Healthcare (Basel) Article Recent advances in next-generation sequencing and genome medicine have contributed to treatment decisions in patients with cancer. Most advanced gynecological cancers develop resistance to chemotherapy and have a poor prognosis. Therefore, we conducted genomic tests in gynecological tumors to examine the efficacy and clinical feasibility of genotype-matched therapy. Target sequencing was performed in 20 cases of gynecological cancers (cervical cancer, 6; endometrial cancer, 6; and ovarian cancer, 6). Both actionable and druggable genes were identified in 95% (19/20) of the cases. Among them, seven patients (35%) received genotype-matched therapy, which was effective in three patients. Of the three patients, one patient with a PTEN mutation received everolimus, another patient with a TSC2 mutation received everolimus and letrozole, and the patient with a BRIP1 mutation received olaparib. Subsequently, disease control in these three patients lasted for more than half a year. However, all patients relapsed between 9 and 13 months after the initiation of genotype-matched therapy. In this study, the response rate of genotype-matched therapy was 43% (3/7), which may have contributed to improved prognoses. Therefore, genotype-matched therapies may help patients with refractory gynecological cancers achieve better outcomes. MDPI 2021-10-19 /pmc/articles/PMC8535840/ /pubmed/34683075 http://dx.doi.org/10.3390/healthcare9101395 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Sawada, Kiyoka
Nakayama, Kentaro
Nakamura, Kohei
Yoshimura, Yuki
Razia, Sultana
Ishikawa, Masako
Yamashita, Hitomi
Ishibashi, Tomoka
Sato, Seiya
Kyo, Satoru
Clinical Outcomes of Genotype-Matched Therapy for Recurrent Gynecological Cancers: A Single Institutional Experience
title Clinical Outcomes of Genotype-Matched Therapy for Recurrent Gynecological Cancers: A Single Institutional Experience
title_full Clinical Outcomes of Genotype-Matched Therapy for Recurrent Gynecological Cancers: A Single Institutional Experience
title_fullStr Clinical Outcomes of Genotype-Matched Therapy for Recurrent Gynecological Cancers: A Single Institutional Experience
title_full_unstemmed Clinical Outcomes of Genotype-Matched Therapy for Recurrent Gynecological Cancers: A Single Institutional Experience
title_short Clinical Outcomes of Genotype-Matched Therapy for Recurrent Gynecological Cancers: A Single Institutional Experience
title_sort clinical outcomes of genotype-matched therapy for recurrent gynecological cancers: a single institutional experience
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8535840/
https://www.ncbi.nlm.nih.gov/pubmed/34683075
http://dx.doi.org/10.3390/healthcare9101395
work_keys_str_mv AT sawadakiyoka clinicaloutcomesofgenotypematchedtherapyforrecurrentgynecologicalcancersasingleinstitutionalexperience
AT nakayamakentaro clinicaloutcomesofgenotypematchedtherapyforrecurrentgynecologicalcancersasingleinstitutionalexperience
AT nakamurakohei clinicaloutcomesofgenotypematchedtherapyforrecurrentgynecologicalcancersasingleinstitutionalexperience
AT yoshimurayuki clinicaloutcomesofgenotypematchedtherapyforrecurrentgynecologicalcancersasingleinstitutionalexperience
AT raziasultana clinicaloutcomesofgenotypematchedtherapyforrecurrentgynecologicalcancersasingleinstitutionalexperience
AT ishikawamasako clinicaloutcomesofgenotypematchedtherapyforrecurrentgynecologicalcancersasingleinstitutionalexperience
AT yamashitahitomi clinicaloutcomesofgenotypematchedtherapyforrecurrentgynecologicalcancersasingleinstitutionalexperience
AT ishibashitomoka clinicaloutcomesofgenotypematchedtherapyforrecurrentgynecologicalcancersasingleinstitutionalexperience
AT satoseiya clinicaloutcomesofgenotypematchedtherapyforrecurrentgynecologicalcancersasingleinstitutionalexperience
AT kyosatoru clinicaloutcomesofgenotypematchedtherapyforrecurrentgynecologicalcancersasingleinstitutionalexperience